|
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer (BC). |
|
|
Consulting or Advisory Role - Lilly; Novartis; Roche |
Speakers' Bureau - Lilly; Novartis |
Research Funding - Roche (Inst) |
Travel, Accommodations, Expenses - Celgene; Tesaro |
|
|
Consulting or Advisory Role - Celgene; Genomic Health; Lilly; Roche |
Travel, Accommodations, Expenses - Celgene; Pfizer |
|
|
No Relationships to Disclose |
|
|
Honoraria - Lilly; Novartis; Pfizer |
Consulting or Advisory Role - Lilly; Novartis |
Research Funding - Novartis |
Travel, Accommodations, Expenses - Gentili; Lilly; Novartis; Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Novartis; Roche |
Travel, Accommodations, Expenses - Novartis; Pfizer; Roche |
|
|
Honoraria - Lilly; Novartis; Pfizer; Pfizer |
Consulting or Advisory Role - Celgene; Novartis |
Travel, Accommodations, Expenses - Novartis; Pfizer; Roche/Genentech |
|
|
Consulting or Advisory Role - AstraZeneca; Merck |
Travel, Accommodations, Expenses - Celgene; Ipsen; Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Novartis; Novartis; Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Lilly; Novartis; Roche/Genentech; Tesaro |
Research Funding - Bristol-Myers Squibb (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Novartis; Pfizer |